Discover
CGTX
Cognition Therapeutics, Inc.
1.13
2 x 0.86
2 x 1.45
bid
ask
-
0.02
1.74%
2 @ 06:30 AM
1.17 +0.04 (3.54%)
| Ytd | -16.30% | |
| 1y | 262.18% |
1.11
day range
1.22
0.32
52 week range
3.83
| Open | 1.18 | Prev Close | 1.15 | Low | 1.11 | High | 1.22 | Mkt Cap | 101.13M |
| Vol | 2.36M | Avg Vol | 1.41M | EPS | -0.23 | P/E | N/A | Forward P/E | -0.80 |
| Beta | 1.33 | Short Ratio | 1.07 | Inst. Own | 24.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 1.24 | 200-d Avg | 1.33 | 1yr Est | 6.50 |
CGTX News
seekingalpha.com
Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain
Cognition Therapeutics is currently prioritizing zervimesine for DLB psychosis. This is after the FD
benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Pulsenmore (NASDAQ:PLSM) shares moved upwards by 160.5% to $8.88 during Wednesday's reg
benzinga.com
FDA Agrees Psychosis Associated With Dementia With Lewy Bodies May Be Approvable Outcome, Reaches Al
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinic
benzinga.com
Cognition Therapeutics Receives Notice Of Allowance From USPTO For Patent Application 19/563,468, Co
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinic